Executive Management

Chris Robillard joined Crinetics as Chief Business Officer in 2022. He brings more than a decade of experience designing and implementing corporate development strategies to capitalize on growth opportunities for biopharmaceutical companies. Prior to Crinetics, Chris served as Vice President and Head of Business Development for Goldfinch Bio, where he worked with leaders across the organization to develop a corporate development strategy that incorporated partnering and funding opportunities. Prior to that, at Karyopharm Therapeutics, he led business development and corporate strategy efforts, driving international expansion while transitioning from a clinical to commercial company. Earlier in his career, Chris held senior positions in business development at Baxalta and in finance at Cubist Pharmaceuticals. 

Chris holds a bachelor’s degree in finance from Lehigh University and a master’s degree in business administration from Pepperdine University.